



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|----------------------|-------------------------|------------------|
| 09/998,961 10/31/2001 | | E. Skott Greenhalgh | 24491-A USA | 6493 |
| 7590 03/10/2004 | | | EXAMINER | |
| John A. Chionchio, Esquire | | | LANDREM, KAMRIN R | |
| Synnestvedt & | Lechner LLP | | | |
| 1101 Market Street, Suite 2600 Philadelphia, PA 19107-2950 | | | ART UNIT | PAPER NUMBER |
| | | | 3738 | |
| | | | DATE MAILED: 03/10/2004 | , 5 |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | <i></i> | | | | |
|--|---|--|--|--|--|--|
| | Application No. | Applicant(s) | | | | |
| | 09/998,961 | GREENHALGH, E. SKOTT | | | | |
| Office Action Summary | Examiner | Art Unit | | | | |
| | Kamrin R. Landrem | 3738 | | | | |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply | | | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failura to reply within the set or extanded period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). | 36(a). In no event, howaver, may a reply be within the statutory minimum of thirty (30) will apply and will expira SIX (6) MONTHS fr causa the application to bacoma ABANDO | timely filed days will be considered timely. om the mailing date of this communication. NED (35 U.S.C. § 133). | | | | |
| Status | | | | | | |
| 1) Responsive to communication(s) filed on 24 No | ovember 2003. | | | | | |
| · | action is non-final. | | | | | |
| , | | | | | | |
| Disposition of Claims | | | | | | |
| 4) ☐ Claim(s) 1,5,7-11 and 13-31 is/are pending in the day Of the above claim(s) 21-29 is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1,5,7-11,13-20,and 30,31 is/are reject 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or | vn from consideration. | | | | | |
| Application Papers | | | | | | |
| 9) The specification is objected to by the Examiner. | | | | | | |
| 10)⊠ The drawing(s) filed on <u>31 October 2001</u> is/are: a)□ accepted or b)⊠ objected to by the Examiner. | | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | | |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. | | | | | | |
| Priority under 35 U.S.C. § 119 | | | | | | |
| 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | | | |
| | | | | | | |
| Attachment(s) | | | | | | |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date | | | | | | |
| Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date I.S. Patent and Trademark Office. | | Date : al Patent Application (PTO-152) | | | | |

Application/Control Number: 09/998,961

Art Unit: 3738

DETAILED ACTION

Allowable Subject Matter

The indicated allowability of claim6-9,11-15, and 17-20 is withdrawn in view of the newly discovered reference(s) to Lazarus (USPN 5,693,088). Rejections based on the newly cited reference(s) follow.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1,5,8,9,30,31 are rejected under 35 U.S.C. 102(b) as being anticipated by Lazarus (USPN 5,693,007).

With reference to Figures 1 and 2, Lazarus discloses a bifurcated graft compatible with living animal tissue said graft comprising an elastic polytetrafluoroethylene elongated tubular substrate having attachment regions 16 positioned at each end, a plurality of pores extending through said attachment region to promote ingrowth and to sealingly attach said substrate to adjacent tissue (5:36-40) thereby making portions between said attachment regions substantially impermeable to fluids (2:47-57). The attachment regions are coated with a substance that promotes healing, such as a collagen material (13:25-46). The attachment regions can be composed of a second material different from that of the other portions of the graft. The second

Page 3

Application/Control Number: 09/998,961

Art Unit: 3738

material, such as polyproplene (5:54+) may be used to elicit a healing response from the living tissue.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 10 and 14-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lazarus in view of Lentz et al (USPN 6,428,571).

Lazarus, as discussed above, discloses the compatible graft as claimed. Lazarus however fails to disclose that the graft can be disclosed of a non-woven ePTFE material. Lentz teaches a vascular graft composed of expanded polytetrafluoroethylene that is defined of elongate fibrils interconnected that create varying degrees of porosity to provide enhanced endothelization due to regions of higher porosity and enhanced strength due to the regions of lower porosity(4:34-52). Therefore in view of the teachings it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the compatible graft disclosed by Lentz to incorporate the ePTFE material as taught by Lentz in order to produce a graft with varying degrees of porosity for improved structural properties and increased tissue ingrowth.

Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lazarus in view of Chouinard (USPN 6,156,064).

Lazarus, as discussed above, discloses the compatible graft as claimed. Lazarus however fails to disclose that the specific permeability of the compatible graft. Chouinard teaches a

Application/Control Number: 09/998,961

Art Unit: 3738

Page 4

compatible PTFE or ePTFE (3:50) that has a permeability range of 50 cc/cm²/min to about 5000 cc/cm²/min to create a graft with an impermeable layer and an permeable layer (1:10-15). Therefore in view of the teachings it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the graft disclosed by Lazarus to incorporate the specific permabilities as taught by Chouinard to produce a graft with regions that are permeable for tissue ingrowth and areas that are impermeable to fluids and tissue to restore flow.

Claims 11,13, and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lazarus as modified by Lentz, further in view of Karwoski et al (USPN 6,042,666).

Lazarus, as discussed above, discloses the compatible graft as claimed. Lazarus however fails to disclose the specific pore size of the compatible graft. Karwoski teaches an endovascular graft with regions that have different pore size (50-500 microns), pore shape and porosity (3:21-53) to produce areas of greater porosity to serve as a microscaffolding structure fore growth of connective tissue and an area having smaller pore structure for reconstituting a biological flow surface through the vessel (3:66-4:4:11). While Karwoski does not specifically recite that the pores are pierced it is inherent that the product formed would have the same end resulting pore size. Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. (See MPEP 2113). Therefore in view of the teachings it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the graft disclosed by Lazarus to incorporate the various pore sizes taught by

Application/Control Number: 09/998,961 Page 5

Art Unit: 3738

Karwoski in order to produce a graft with portions that promote ingrowth and areas that are impermeable and promote blood flow.

Response to Arguments

Applicant's arguments filed November 24, 2003 have been fully considered but they are not persuasive.

Applicant's election with traverse of Species A and sub-species a (Figures 2 and 3) in Paper No. 4 is acknowledged. The traversal is on the ground(s) that there would not be a serious burden on the Examiner if all pending claims were searched. This is not found persuasive because there are several embodiments present in the claims. The embodiment shown in Figures 4 and 5 have a textured surface with loops as opposed to the porous surface shown in the embodiments in Figures 2 and 3.

The requirement is still deemed proper and is therefore made FINAL.

Applicant's arguments with respect to claims 1-31 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kamrin R. Landrem whose telephone number is 703-305-8061. The examiner can normally be reached on 8:00-5:00, Monday-Friday.

Art Unit: 3738

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on 703-308-2111. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kamrin Landrem Examiner AU 3738

KRL

David J. Isabella Primary Examiner